Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...
WHO has prequalified two Covid-19 rapid antigen tests for the first time, confirming long-term quality and enabling UN ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has ...
Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...
GlobalData on MSN
Fulgent Genetics to buy Bako Diagnostics assets and StrataDx
The addition of Bako and StrataDx is anticipated to bolster Fulgent’s lab services business with the inclusion of new ...
WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...
GraftAssure technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx FDA IVD approval application 95% complete at yea ...
The World Health Organization (WHO) announced the prequalification of two rapid antigen diagnostic tests (Ag-RDT) for ...
Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian ...
Fulgent Genetics ( ($FLGT) ) has shared an update. On December 20, 2025, Fulgent Genetics’ subsidiary Inform Diagnostics signed agreements to buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback